Mention prostate health to young men and they’ll dismiss it as something they will only have to worry about when they get ...
The US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognized a favorable benefit risk profile for AstraZeneca’s TRUQAP® (capivasertib) in combination with ...
A new pretargeted radioimmunotherapy (PRIT) technique has been shown to be safe and effective in eradicating tumors from a ...
The "Provenge Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The report outlines essential statistics, market ...
Men diagnosed at screening aged 50 years projected to have 16% chance that cancer would not have been detected within 15 ...
Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The ...
Advanced age raises mortality risk in metastatic prostate cancer. Learn how PSA, tumour grade, and treatment influence ...
Patients with cardiovascular-kidney-metabolic syndrome, especially those in the advanced stages at baseline, show a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results